<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T01:29:14Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/29010" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/29010</identifier><datestamp>2026-09-24T18:55:52Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Shoamanesh, Ashkan</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Balali, Pargol</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Neuroscience</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2023-10-06T18:24:05Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2023-10-06T18:24:05Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2023</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/29010</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/19243</dim:field>
   <dim:field mdschema="dc" element="description" lang="en_US">Balali_Pargol_MSc thesis_Neuroscience department_2023Sep</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Background: Cerebral microbleeds are asymptomatic neuroimaging markers of small&#xd;
vessel disease (SVD), visualized as small hypointensities on blood-sensitive magnetic&#xd;
resonance imaging (MRI) sequences. Patients with ischemic stroke and microbleeds are&#xd;
at a higher risk of future ischemic stroke and intracranial hemorrhage. Antithrombotic&#xd;
therapies, the mainstay treatment of secondary stroke prevention, are associated with an&#xd;
increased risk of bleeding. This raises concerns surrounding the net benefit of&#xd;
antithrombotic therapies in these hemorrhage-prone patients. The overarching aim of this&#xd;
thesis is to determine the safety of antithrombotic treatments in patients with hemorrhage-prone SVD marked by microbleeds on MRI or prior intracerebral hemorrhage (ICH). I&#xd;
aimed to characterize the association between baseline microbleeds and the risk of future&#xd;
clinical outcomes in patients with ischemic stroke and whether there exists treatment&#xd;
effect modification of different anticoagulants on clinical outcomes according to&#xd;
microbleeds presence, location, and number.&#xd;
Methods: We performed post hoc analyses on two multicenter previously conducted&#xd;
randomized trials in patients with non-cardioembolic ischemic stroke. For the PACIFIC-STROKE trial, we used multivariable regression models to determine the contribution of&#xd;
microbleeds to the risk of new microbleeds, hemorrhagic transformation (HT), ischemic&#xd;
stroke, intracranial hemorrhage, and death. We assessed the treatment effect of&#xd;
asundexian, a factor XIa inhibitor, vs. placebo on these clinical outcomes, stratified by&#xd;
microbleeds presence, location, and number.&#xd;
I was trained on standardized rating of microbleeds on MRI, achieved excellent interrater&#xd;
reliability, and rated all DATAS-II participant MRIs. I used multivariable logistic&#xd;
regression models to identify the association between microbleeds and HT and 90-day&#xd;
excellent functional outcome. I assessed the interaction between treatment with&#xd;
dabigatran, a direct thrombin inhibitor, vs. aspirin and microbleeds for these outcomes.&#xd;
Separately, I performed a review of the literature and wrote an editorial discussing the&#xd;
optimum timing of antiplatelet re-initiation after ICH.&#xd;
Results: The PACIFIC-STROKE post hoc analyses showed that microbleeds are&#xd;
associated with a 1.6-fold and 4.4-fold higher risk of HT and new microbleeds,&#xd;
respectively. The DATAS-II exploratory analyses demonstrated no association between&#xd;
the risk of outcomes and microbleeds presence. We found no interaction between&#xd;
treatment assignment and microbleed presence for any of the clinical outcomes&#xd;
investigated in either of these studies. Based on the totality of evidence, we concluded&#xd;
that early resumption of antiplatelets in ICH survivors is likely to be safe.&#xd;
Conclusion: Our findings do not support existing concerns surrounding the use of&#xd;
anticoagulants in patients with acute ischemic stroke and microbleeds on MRI, nor for the&#xd;
early resumption of antiplatelets in ICH survivors.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Science (MSc)</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="layabstract" lang="en_US">Diseases of small brain blood vessels can lead to strokes due to blockage or&#xd;
bleeding. Small, asymptomatic brain bleeds on MRIs (microbleeds) are common among&#xd;
affected patients. Patients with clot-induced stroke and microbleeds have a higher risk of&#xd;
both types of strokes. Blood thinners are standard treatments to prevent future clotting&#xd;
events after clot-induced stroke. However, their potential to increase the risk of brain&#xd;
bleeding has raised concerns regarding their use in patients with microbleeds or bleeding-induced stroke.&#xd;
We assessed information from two large, previously completed randomized trials&#xd;
to evaluate the safety of strong blood thinners (anticoagulants) in patients with clot-induced&#xd;
stroke and microbleeds. Additionally, we evaluated the risk vs. benefit of&#xd;
restarting milder blood thinners (antiplatelets) early after bleeding-induced stroke.&#xd;
Bleeding was more prevalent in patients with microbleeds; however, the effect of&#xd;
the anticoagulants tested on bleeding outcomes was not modified by microbleed&#xd;
presence. Overall, our findings suggest that blood thinners are safe in patients with clot-induced stroke and microbleeds, and that early resumption of antiplatelets seems safe in&#xd;
patients with bleeding-induced stroke.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en_US</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Microbleeds</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Ischemic stroke</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Stroke prevention</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Anticoagulation</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Cerebral small vessel disease</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Intracerebral hemorrhage</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Risk-benefit of Antithrombotic Treatment in Patients with Hemorrhage-prone Cerebral Small Vessel Disease</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>